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Build and validate baseline model
• In vitro studies (EP/Ca2+)
• Imaging (MRI, CT, microscopy)
• IPSC cardiomyocyte EP
• Metabolism
Gating models         Cellular models
Structural models
Validation Simulation
Define and quantify the substrate
• Next generation sequencing
• Imaging (CMRI, CT)
• In vivo studies (PEF)
• In vitro studies (EP/Ca2+/metabolism)
Define and quantify triggers
• Ectopic beats
• Heart rate dynamics
• Acute ischaemia
• Adrenergic stimulation
Deep ECG phenotyping
• Holter (rate dependent trends)
• Waveform morphology
• Novel biomarkers
Clinical trials
• Drug screening tools
• Automated diagnosis
• Risk stratification
Proarrythmic biomarkers
Risk stratification algorithms
(i)  Develop baseline model
(ii)  Disease specific simulations
(iii)  Translation
Priority goals for computational 
cardiology
1.  A model of calcium cycling scalable 
     to tissue and organ level simulation
2.  A consensus model of adrenergic 
     effects on cardiac electrophysiology
3.  Development of IPSC derived 
     cardiomyocytes for model validation
4.  Continuation of efforts to build 
     central repositories and tools for 
     sharing and validation of models
5.  Establishment of deep ECG 
     phenotype resources
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Abstract Risk stratification in the context of sudden cardiac death has been acknowledged as
one of themajor challenges facing cardiology for the past four decades. In recent years, the advent
of high performance computing has facilitated organ-level simulation of the heart, meaning we
can now examine the causes, mechanisms and impact of cardiac dysfunction in silico. As a result,
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computational cardiology, largely driven by the Physiome project, now stands at the threshold
of clinical utility in regards to risk stratification and treatment of patients at risk of sudden
cardiac death. In this white paper, we outline a roadmap of what needs to be done to make this
translational step, using the relatively well-developed case of acquired or drug-induced long QT
syndrome as an exemplar case.
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Abstract figure legend Proposed roadmap for computational cardiology. A, general approach for clinical application of
computational cardiology outlining three stages of development: (i) development of baselinemodels; (ii) disease specific
simulations; and (iii) translation. At each state black arrows represents the iterative process of in silico simulation and in
vitro/in vivo validation that is critical for successful implementation. The human ventricular mesh was provided by Dr
Mikael Wallman and Professor Blanca Rodriguez, and developed as described inWallman et al. 2014. B, specific priority
goals for convergence of computational and clinical cardiology. Expanded discussion of specific goals is presented in the
section headed The future: moving computational cardiology into the clinic.
Abbreviations aLQTS, acquired long QT syndrome; CICR, calcium-induced calcium release; CiPA, comprehensive
in vitro proarrhythmic assay; EC, excitation–contraction; ECG, electrocardiogram; EP, electrophysiology; HPC, high
performance computing; HR, heart rate; ICD, implantable cardioverter defibrillator; IPSC, induced pluripotent stem
cell; SCD, sudden cardiac death; SR, sarcoplasmic reticulum; TdP, torsades de pointes.
The challenge
Sudden cardiac death (SCD), which is most commonly
caused by cardiac arrhythmias, accounts for 10% of all
deaths in developed countries (de Vreede-Swagemakers
et al. 1997; Deo&Albert, 2012). Patients who suffer a SCD
have some underlying cardiac pathology, even if they were
unaware of it at the time. While implantable cardioverter
defibrillators (ICDs) appear very effective at reducing the
incidence of SCD, they remain expensive, and are not
devoid of significant adverse effects such as inappropriate
shocks, broken leads requiring invasive replacement,
infections, and surgical complications, particularly in
paediatric patients (Rosenqvist et al. 1998; Schimpf et al.
2003; Olde Nordkamp et al. 2015). Therefore, in order
to optimise the use of ICDs, there is a critical need
to correctly identify the patients who are at most risk
and so most likely to derive benefit. At present our
ability to identify these patients is poor and largely
based on non-specific associations such as the extent
of contractile dysfunction in patients with heart failure
(Stevenson & Epstein, 2003), or altered cardiac auto-
nomic function (Nagahara et al. 2008). In the modern
era of genomics-inspired precision medicine, surely we
can do better? In the last 20 years we have made great
strides in understanding the molecular and cellular events
underlying cardiac arrhythmias (Keating & Sanguinetti,
2001; George, 2013). The challenge now is to translate this
knowledge into improved prediction and prevention of
cardiac arrhythmias and SCD in patients.
Integrating the activity of the dozens of different
types of ion channels and electrogenic transporters in
multiple different cell types that underlie the electrical
signals recorded on the electrocardiogram (ECG) is an
extraordinarily complex task. Indeed, over 50 years ago
Denis Noble, co-founder of the Human Physiome project
(Hunter et al. 2002; Hunter & Borg, 2003), recognised
that it could only be achieved using high performance
computing (HPC). Today’s computers are many orders of
magnitude more sophisticated and modelling of cardiac
electrical activity is probably the most advanced of all the
different components of the Human Physiome project.
Even so, computational cardiology is not yet sufficiently
advanced that it can be directly applied in the clinic.
However, the establishment of a multitude of start-up
companies in this space suggests that we could be on
the cusp of a revolution. Perhaps the strongest evidence
to suggest that this may be the case is the Food and
Drug Administration in the USA investing significant
resources in the comprehensive in vitro proarrhythmia
assay (CiPA) initiative. This new paradigm has in silico
modellingasoneof its core components for thepre-clinical
assessment of the proarrhythmic risk of all new drugs
prior to clinical development (Sager et al. 2014; Fermini
et al. 2016).
In this white paper, we will discuss the requirements
for computational cardiology to become a reality in the
context of predicting risk of cardiac arrhythmias. As a
first step, we propose a roadmap for the development of
such application and then discuss recent progress with
the CiPA initiative and risk stratification for drug-induced
or acquired long QT syndrome (aLQTS) as an exemplar
case.
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A proposed roadmap for computational
cardiology
Arrhythmias are often discussed as falling into three
groups: (1) triggered activities caused by early or
delayed after depolarisations that may manifest as tachy-
arrhythmias; (2) altered automaticity resulting in either
brady- or tachycardia; and (3) re-entrant, where circus
movement around areas of anatomical or functional block
manifests as monomorphic/polymorphic ventricular
tachycardia or fibrillation, depending on the stability
and anchoring of the rotor (Antzelevitch & Burashnikov,
2011; Qu & Weiss, 2015). More recently, discussion has
focused on the concepts of underlying substrates (that
may be either structural or electrical in nature) that permit
re-entry and how they may interact with triggers in the
genesis and maintenance of sustained arrhythmias (Kalin
et al. 2010). The challenge in developing computational
approaches to risk stratification for arrhythmias is to
accurately define what we mean by substrates and
triggers, and then to quantify these factors such that we
can use them to generate mathematical models that can
be validated against quantifiable outcomes. Lastly, and
more importantly, the models then need to be able to
makequantitativepredictions that canbe tested against the
endpoint of clinical concern: proarrhythmia (see Abstract
figure).
Defining and quantifying substrates
for arrhythmogenesis
Arrhythmias are emergent properties of intact tissue.
Nevertheless, tissues are made up of cells and molecules
and so quantifying tissue level properties will also
require quantifying the genetic/molecular as well as
cellular/intercellular components that make up tissues.
For example, consider the scar tissue that forms after a
myocardial infarct. At a tissue level, the extent of the
scar tissue should be imaged as accurately as possible,
as well as the relative distribution of fibroblasts versus
extracellular matrix within the scar and border zone.
Within these regions it is also important to under-
stand the degree of remodelling of electrical and calcium
handling properties, as well as the extent and spatial
heterogeneity of sympathetic denervation (Li et al. 2004;
Gardner et al. 2015). Ideally, one should also be aware of
the genetic makeup of patients in order to comprehend
potential impact on their baseline electrophysiological
profiles. Adding further complexity, dynamic changes to
the substrate such as variation in extracellular electro-
lytes, alterations in blood flow and supply of oxygen and
nutrients secondary to acute episodes of ischaemia are
important as they may explain, at least partly, why the
same triggers can initiate arrhythmias on some occasions
but not others. Finally, when thinking about dynamic
changes it is also important to consider timescales. The
above modifications are likely to occur over minutes to
days. However, more rapid changes such as changes in
heart rate (HR) can also alter how triggers will interact
with the substrate.
Defining and quantifying triggers for cardiac
arrhythmias
It has long been recognised that an appropriately timed
premature beat, i.e. a trigger delivered during the so-called
‘vulnerable window’, has the propensity to initiate an
arrhythmia (Mines, 1914). Indeed, the programmed
application of premature, often multiple beats, forms
the basis of most invasive electrophysiology (EP) studies
aimed at determining the inducibility of arrhythmias
(Doherty et al. 1983; Hummel et al. 1994). One challenge
though is defining the conditions that determine a trigger
in the setting of a dynamic substrate. For example,
an ectopic beat delivered at a given coupling inter-
val may not initiate an arrhythmia when the under-
lying HR is fast, but may do so when the underlying
HR is slower. Furthermore, an ectopic beat of a given
coupling interval and underlying HR may be more or less
proarrhythmic depending on the prevailing autonomic
tone. Fortuitously this is precisely where computational
approaches can bemost useful. In such complex scenarios,
the very large number of combinations of variablesmay be
prohibitive to test in wet lab experiments. However, with
sufficient computational power hundreds and thousands
of combinations of variables can be readily tested in silico
and then only the critical variable combinations tested
in situ or in vivo.
Developing mathematical models
When it comes to quantifying each variable and
incorporating them into mathematical models, another
factor that we need to consider in the face of
such a challenging and complex phenomenon, is how
comprehensive do these models need to be – and to
what extent can they be simplified? Bearing in mind the
dictum that ‘all models are wrong but some are useful’
(Box, 1976) – we need to include enough information
for models to be useful, but no more than is appropriate
for the task, given the constraints of computational load
as well as limitations in properly constraining the model.
Fortunately, this is a challenge that has been embracedover
many decades, starting with the pioneering work of Denis
Noble (Noble, 1962). As a result, we now have a wealth of
model frameworks from the single-channel level, through
to the whole-heart to work with. Nevertheless, if we are
going to reach the summit of developing models that have
genuine clinical utility then understanding the limitations
of each component of eachmodel, and determining where
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simplification can and should (and indeed should not) be
made, is always going to be critical. Inevitably, this will
be an iterative process. It will be critical to use data that
provide quantitative limits on substrates and triggers, to
ensure that themodels ultimately will produce predictions
that are relevant to arrhythmias.
A particularly good example of an area in which model
development and the assessment of the most appropriate
level ofmodel complexitymerits close attention is calcium
handling and excitation–contraction (EC) coupling.
Calcium signalling is tightly coupled to the electrical
properties of the heart, such that any disturbance to the
electrical system will affect calcium signalling, and vice
versa. Therefore, in understanding both the genesis and
functional consequences of rhythm disturbances that can
lead to SCD, this is a critical area of focus. There has been a
huge amount of work exploring themolecular and cellular
basis of calcium handling in isolated cardiac myocytes
and its contribution to EC coupling (Bers, 2001, 2002).
However, modelling calcium handling even at a single cell
level is much more complex than describing the electrical
properties of the cell. In the case of modelling intra-
cellular calcium concentrations, both spatial gradients
and microarchitecture of the subcellular compartment
are potentially just as important as temporal changes,
making this a much more computationally challenging
problem. Over the years, modelling approaches to this
phenomenon have evolved as our knowledge of intra-
cellular calciumhandling has grown. Starting withmodels
where intracellular calcium exists purely as a function of
calcium influx through the plasma membrane (Beeler
& Reuter, 1977), we have seen the addition of intra-
cellular compartments (the sarcoplasmic reticulum) that
sequester and release calcium (DiFrancesco & Noble,
1985), linking of these compartments to membrane
calcium currents to describe calcium-induced calcium
release (CICR) (Luo & Rudy, 1994) and addition
of diffusion restricted sub-compartments of the cyto-
plasm approximating the environment of the junctional
SR–T-tubule interface (Jafri et al. 1998). The modelling
of calcium homeostasis has been subsequently refined
to include more accurate representations of calcium
removal mechanisms and the dependence of CICR on
SR load (Shannon et al. 2004; Grandi et al. 2010), the
kinetics of phosphorylation of calcium handling proteins
by CaMKII (Iribe et al. 2006), and updates of L-type
calcium current and Na+–Ca2+ exchanger based on data
from human ventricular tissue (O’hara et al. 2011). In all
of these models, calcium concentration is spatially homo-
genised in each compartment, i.e. takes the same value
everywhere in the compartment at a given time. More
recently, microdomain models have been developed that
include structural as well as molecular descriptions of the
dyadic cleft to varying degrees of accuracy (Schendel &
Falcke, 2010; Schendel et al. 2011; Cannell et al. 2013;
Stern et al. 2013), that can be scaled up to describe
whole cytoplasmic calcium concentrations (Higgins et al.
2007; Restrepo et al. 2008; Rovetti et al. 2010; Gaur &
Rudy, 2011; Nivala et al. 2015; Vierheller et al. 2015).
This reductionist approach necessitates the simulation of
tens of thousands of dyads per cell, requiring significant
computational times between ten minutes to many hours
for a single beat of an individual cell, depending on the
level of detail included (Nivala et al. 2012; Vierheller
et al. 2015). As a result, while this certainly represents
a gold standard for simulation of calcium dynamics in
single cells, it presents a problem for consideration of
larger scale tissue or organ level simulations that will
likely require implementationofmultiscale computational
strategies. This example therefore embodies perfectly
the conundrum described above, of selecting models of
appropriate level of complexity for the task at hand. It also
highlights an areawhere particular focus shouldbe applied
in advancing numerical techniques or taking advantage of
new, more powerful parallel computing hardware (Tuan
et al. 2011; Chai et al. 2013), such that more complete
descriptions of calcium handling can be incorporated into
tissue level simulations.
Model validation
Once we have established the required models, thorough
validation is critical, and this must use datasets
independent of those used to generate the models in the
first place. At the cellular level, one area of growth that
will no doubt play a central role in validating cellular
models is the use of cardiomyocytes derived from human
induced pluripotent stem cells (IPSC) (Takahashi &
Yamanaka, 2006;Narsinh et al.2011). IPSCderived cardio-
myocytes from patients with normal as well as diseased
hearts present a platform for studying cardiac diseases
(Carvajal-Vergara et al. 2010; Moretti et al. 2010) or drug
effects (Sinnecker et al. 2014) in a more faithful biological
context. Critically, these ‘hearts in a dish’ maintain many
intrinsic disease characteristics and genetic background of
the patient, and so represent a powerful tool to study the
mechanisms of disease, or the actions of drugs, without
the ethical and practical implications of collecting human
cardiac tissue.However, this technology is still in its relative
infancy. In particular, issues exist around the relative
immaturity of these cells and how well they reflect the
function and morphology of the adult ventricular myo-
cyte in relation to electrophysiology, calcium handling
and responses to adrenergic stimulation for example
(Laflamme &Murry, 2011). It is certainly true that efforts
are already well underway to tackle this issue. Aside from
long term culture on the order of months to years (Otsuji
et al. 2010), more recent efforts have focused on efforts
to mimic more closely the environment of the developing
heart and drive these cells to a more adult phenotype such
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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as 3D culture and mechanical stimulation (Nunes et al.
2013; Mihic et al. 2014), electrical stimulation (Eng et al.
2016) and co-culture with non-cardiomyocyte cells (Kim
et al. 2010; Saini et al. 2015). Culturing of IPSC derived
cardiomyocytes on microgrooved substrates has proved
particularly effective in promotingmore adult-like cellular
morphology aswell sarcomericorganisation, that in turn is
important for defining the subcellular spatial restrictions
necessary for normal calcium homeostasis. Under these
conditions, cells showed calcium transients that more
faithfully reflected those observed in adult myocytes (Rao
et al. 2013). These approaches have therefore shown a
great deal of promise in promoting both electrical and
morphological maturity, yet there is no doubt that these
cells are still more fetal than adult in nature. Despite this,
the technology is rapidly being embraced – most notably
as part of the CiPA initiative (Sager et al. 2014). As such,
it is critical that issues surrounding maturation of IPSC
derived cardiomyocytes are tackled such that this rapidly
emerging field can play a central role in the validation and
construction of cellular electrophysiological models.
Ultimately though, sudden cardiac death represents the
final common endpoint of abnormal electrical signalling
in the organ, i.e. is not solely a cellular phenomenon. First
and foremost therefore, any computational model must
be able to reproduce, at a quantitative level, the electrical
signals recorded from patients. In this regard, we foresee
a very important role for deep ECG phenotyping and
specifically for high-resolution analysis of Holter ECGs
that provide information on how the electrical signalling
in the heart responds to a wide range of physiological
stimuli. Until recently, the analysis of Holter ECGs has
been limited (due to the relatively large volumes of data
acquired compared to the computational power available
to analyse them). Recent increases in computer processing
power and storage capacity have largely obviated this
problem, but there is still a lot that can and should be
done to develop better software packages for analysing
multi-lead Holter ECG datasets, which will be very useful
for validating computational models. This again should
be seen as an iterative process and indeed one can envisage
that this process will lead to identification of better
biomarkers of cardiac electrical activity that in themselves
may provide better means for stratifying risk of SCD.
Drug-induced arrhythmias: a case study
for in silico risk prediction
In the past 15 years, a range of structurally unrelated
non-cardiovascular drugs have been withdrawn from the
market due to adverse effects on cardiac repolarisation
and risk of heart rhythm disturbances – so called
acquired or drug-induced long QT syndrome (aLQTS)
(Wood & Roden, 2004). These drugs include anti-
histamines, antibiotics, antipsychotics and most recently
the analgesic propoxyphene, which was prescribed to an
estimated 10 million patients in the US at the time of
its withdrawal in 2010. The aLQTS is characterised by
delayed repolarisation, prolongation of the QT interval
on the surface electrocardiogram (ECG) and a markedly
increased risk of a potentially lethal ventricular arrhythmia
named torsades de pointes (TdP) (Wood & Roden, 2004;
Kannankeril et al. 2010). aLQTS can be caused by drugs
that block any of the ionic currents that contribute to
repolarisation of the heart. In practice, however, the vast
majority of drugs that can cause aLQTS do so by inhibiting
hERG channels (Perrin et al. 2008b). This observation
led to the current suite of guidelines relating to cardiac
safety that were issued in 2005: recommending that, at
a minimum, all compounds are subject to an in vitro
evaluation of hERG block together with assessment of
in vivoQT interval prolongation in an appropriate animal
model (ICH S7B) and an assessment of QT prolongation
in humans (ICH E14) (Food and Drug Administration,
HHS, 2005a,b).
These guidelines have several important shortcomings.
First amongst them is that while the tests are very sensitive,
and have been successful in eliminating dangerous drugs,
they are believed to be insufficiently specific. Neither
hERG block nor QT prolongation are good predictors
of risk of TdP (Sager et al. 2014). There is also growing
concern that this approach has led to the premature
termination of the development of drugs based on their
hERG affinity, rather than propensity to actually cause
arrhythmia. In the context of the roadmap outlined in
the Abstract figure, potency of hERG block and QT
prolongation do not provide sufficiently accurate markers
of the proarrhythmogenic substrate to be useful for
quantifying risk. These shortcomings are acknowledgedby
the regulatory agencies, which has led to the establishment
of CiPA. This initiative is set to change the regulatory
guidelines around cardiac safety testing to a multi-ion
channel, rather thanhERG-centric approach, that is driven
by in silico risk prediction (Sager et al. 2014; Fermini et al.
2016). This new approach will take into account detailed
characterisationofmolecular pharmacology including ion
channel–drug interaction kinetics as well as multichannel
block profiles with the idea that simulations of cardiac
electrophysiology based on this mechanistic insight will
better identify proarrhythmic drugs.
However, while CiPA focused on the use of single cell
modelling for prediction of proarrhythmic propensity, in
reality the genesis of arrhythmia in the intact heart involves
so much more than solely the molecular interaction of
ligand and target. Drugs that block the hERG channel
both delay repolarisation and increase the dispersion of
repolarisation across the heart (Kannankeril et al. 2010).
The delayed repolarisation is considered to increase the
probability of reactivation of L-type calcium channels
leading to early after-depolarisations (EADs) that could
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act as the ‘trigger’ for arrhythmia (January&Riddle, 1989).
Additionally, the increased transmural repolarisation
heterogeneity produces regions of functional block and
slow conduction that provide an intramural substrate
for re-entry (Akar & Rosenbaum, 2003). Although we
understand in principle the tissue level mechanisms of
arrhythmogenesis in aLQTS, the link between hERGblock
and the emergent arrhythmia is complex. However, the
processes that need to be in place to interrogate this in silico
are relativelywell established,meaning the aLQTSexample
is an ideal illustration of the computational risk prediction
pipeline outlined in the Abstract figure. The specifics of
model development, defining and quantifying substrates
and identificationofnovel riskbiomarkers frommultiscale
models in relation to aLQTS are discussed below.
Development and optimisation of models for in silico
risk prediction in aLQTS
An important step in the pursuit of effective in silico
risk prediction is the selection and optimisation of the
molecular and cellular models used for studying the
action of pharmaceutical compounds. At the cellular
scale, we need to reach a consensus on an appropriate
action potential model. This is a critical step given
the dramatic range in action potential morphology that
exists between published models (Cooper et al. 2016) as
well as the intrinsic properties of the models, such as
forward/reverse rate dependence, that must be considered
in understanding how individual models respond to
external perturbations (Cummins et al. 2014). In either
case, variation in maximal current densities (maximal
‘conductances’ in the case of ion channels) is a major
source of discrepancy between predictions from different
models.Unfortunately,most of these conductances are not
easy to measure directly, particularly from healthy human
cardiomyocytes, and have to be inferred from action
potential recordings and cell-level behaviour. While some
recentmodels of the ventricular action potential have been
based on data from healthy human hearts (O’hara et al.
2011), there is still work to be done in tuning thesemodels
for the range of physiological stressors that are critical
in arrhythmogenesis such as their responses to adrenergic
stimulation. In this regard, the use of IPSC derived cardio-
myocytes (see Model validation section, above) will no
doubt contribute to providing the datasets necessary for
this ongoing model development and validation.
Equally important in determining model predictions
is the choice of model for each ion current, specifically
concerning channel gating kinetics in control conditions.
Here,mostmodels useHodgkin–HuxleyorMarkovmodel
structures for the ion channel states and transitions. This
is not a simple task. For example, there are at least seven
different published model structures for the IKr current
alone (Noble et al. 1998; Lu et al. 2001; Piper et al. 2003;
Adeniran et al. 2011; Bett et al. 2011; Di Veroli et al.
2013b). When we consider different parameterisations of
thesemodel structures (different transition rates and their
voltagedependence), there areover thirtypublishedmodel
variants for IKr. There is therefore uncertainty in both
the model structure/equations and also the parameters
which should be used (see Mirams et al. (2016): another
white paper in this issue).Quantifying this uncertaintywill
be an important goal in the coming years, and will
be necessary to place an appropriate level of trust
in model predictions (Johnstone et al. 2015). As part
of this effort, we should quantify which experiments
provide information on parameters and structures: a
whole sub-field of statistics/control theory called ‘optimal
experimental design’ is dedicated to this task, but only a
few steps have been taken so far in applying this to cardiac
modelling (Dokos & Lovell, 2004; Fink & Noble, 2009;
Groenendaal et al. 2015). It is also worth noting that a
perfect fit to training data is not a sign that the model
will be predictive in future, particularly if multiple model
structures and/or parameter sets provide an equally good
fit (Fink et al. 2011). Models should always be evaluated
in the context of predicting an outcome that they were not
trained to replicate.
Each of these factors, the selection of cellular and
molecular models, have important bearing in terms of
evaluating predictions of drug-induced proarrhythmic
risk, such as those envisaged by CiPA, where in silico pre-
dictions are currently based mostly on fits to standardised
in vitro datasets. In this regard, a gold-standard model for
use in computational evaluation of proarrhythmic risk
may be the largest gap in our knowledge. Careful choice
and further calibration and validation of ion current and
action potential models remains one of the fundamental
challenges for computational physiology in the coming
years that is necessary to predict proarrhythmia associated
with acquired LQTS more accurately. To ensure trans-
parency and engender confidence in such computational
approaches, we need to publish: (i) training data; (ii)
calibration/fitting and selection algorithms that give
rise to the final model; and (iii) validation data and
performance metrics. This approach is in line with the
general trend within science of moving towards ‘open
data’ with a view to ensuring reproducibility, especially
in computational science. In this regard, platforms
such as Zenodo (hosted at CERN), datahub.org and
researchcompendia.org provide the infrastructure for
publishing and sharing of scientific data and models
while many discipline specific repositories have also been
built in recent years (see e.g. NIH Data repositories:
https://www.nlm.nih.gov/NIHbmic/nih_data_sharing_
repositories.html). Of particular relevance to the
Physiome community, the CellML effort allows us to
sharemodel equations and parameters easily and provides
a forum for model curation to ensure consistency of
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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implementation between groups (Lloyd et al. 2008),
while the recently established Cardiac Electrophysiology
Web Lab (Cooper et al. 2016) allows functional curation
of CellML encoded models, letting users compare and
contrast how different models behave in response to
a suite of virtual protocols. Perhaps the research field
in which the discussion around data/model sharing is
most advanced is genomics. The Broad Institute recently
published white paper discussing the international
standards and computational needs to share and integrate
data in a secure, controlled and interpretable manner
(Alliance, 2014). This can serve as a worthy template
for the action that should be taken by the Physiome
community which should be encouraged and indeed
mandated by funding agencies and consortium heads to
ensure reproducibility in our discipline.
Defining and quantifying substrates in aLQTS
In the aLQTS the primary substrate is abnormal electrical
function precipitated by the block of cardiac ion channels
(primarily hERG) as a side-effect of both cardiac and
non-cardiac drugs. Specifically, the disruption of the
repolarisation reserve is thought to amplify transmural
spatial dispersion of repolarisation, establishing voltage
gradients that can act as a substrate for re-entry
(Antzelevitch, 2007), while other factors such as temporal
dispersionof repolarisation (i.e. beat tobeat instability) are
also thought to contribute (Frommeyer & Eckardt, 2015).
The challenge of quantifying the substrate therefore lies
in accurately defining and modelling the pharmacology
of drug–channel interactions in the context of the cardiac
action potential. To do this requires that we revisit the
question of what degree of complexity these models
must encapsulate to make in silico prediction of their
proarrhythmic propensity a reality?
Measuring and modelling hERG block. Whilst it is
certainly true that potency of block is not a good indication
of proarrhythmia (Redfern et al. 2003; Di Veroli et al.
2013a), a key outstanding question in determining the
extent to which it is necessary to develop biophysically
accurate models of drug binding is: are the kinetics of
drug interaction with hERG, and indeed other channels,
important in determining proarrhythmic risk? In support
of this concept, Di Veroli et al. proposed that kinetics,
rather than multichannel block profiles, might underlay
the difference in proarrhythmic propensity between the
drugs verapamil and bepridil (Di Veroli et al. 2013a).
More recently, Lee et al. demonstrated in silico how the
kinetics of drug binding can modify both the degree of
prolongation observed with an IC50 concentration of drug
well as the Action Potential (AP) morphology, in terms of
the degree of triangulation for example (Lee et al. 2015),
that reflect likely differences in the associated risk profile
(Hondeghem& Carlsson, 2001). This study, however, was
completely theoretical, and it remains to be seenwhere real
drugs fall into this theoretical landscape, and whether the
range of kinetics observed in vitro allows for these complex
dependencies.
When generatingmodels of the kinetics of drug binding
to ion channels, many of the same issues that arise in
relation to modelling ion channel function also come to
light. Multiple published models exist whose structures
vary according to considerations such as to which states
does a compound bind/unbind (Di Veroli et al. 2013a);
is binding voltage dependent (Moreno et al. 2011);
do drugs get trapped behind a closed activation gate
(Mitcheson et al. 2000); or does drug binding alter the
intrinsic gating behaviour of the channel (Lee et al.
2015)? The key to addressing these issues in silico lies with
accurately measuring and modelling the kinetics of drug
binding to hERG (as well as other channels). Much of the
complexity in achieving this stems from the fact that drugs
can differentially bind to the open and inactive states of
the hERG channel (Suessbrich et al. 1997; Walker et al.
1999; Weerapura et al. 2002; Perrin et al. 2008a). Most
studies assessing binding kinetics depend on complex
voltage protocols that result in cycling of the channel
between open and inactive states in a voltage dependent
manner (Vandenberg et al. 2012). As a result, it is difficult
to confidently deconvolute drug binding kinetics from
voltage dependent channel gating. One way to tackle
this problem is to directly monitor the drug–channel
interaction at a single voltage (Milnes et al. 2010; Hill
et al. 2014). Using similar approaches with other drugs
presents us with the opportunity to accurately model the
mechanism by which drugs block the hERG channel, and
interrogate in detail questions relating to drug binding
kinetics. For example, how do the kinetics of binding and
unbinding vary with temperature? This is a question that
is critical to answer if we want to extrapolate from data
acquired in high throughout systems at room temperature
to physiological temperatures in silico. How do the kinetic
properties of the drug correlate with the observance of
proarrhythmic markers such as triangulation, reverse use
dependence, instability and dispersion (TRIaD criteria)
and indeed do any specific kinetic properties correlate
with risk?
With a view to answering these questions, a central
tenet of CiPA is to include kinetics of block, rather than
just potency, in their in silico models to estimate risk.
However, CiPA is bound by practicalities of industrial
screening in the extent to which kinetics can be measured.
For example, most high-throughput patch clamp systems
are not able to switch perfusion solutions fast enough to
allow direct, accurate measurement of drug binding and
unbinding. Furthermore, the extent to which the kinetics
of drug binding are actually important in determining
risk is not yet fully understood. As a result, first-pass
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measures of drug-binding kinetics deemed appropriate for
CiPAmay not necessarily equate to the more academically
attractive endpoint of fully characterising the kinetics
of drug binding in order to constrain mechanistically
accurate models of the interaction. However, it is clear the
most effective and efficient approach to tackle this problem
in the coming years is to leverage the resources and
expertise available across the range of stakeholders from
academia, the pharmaceutical industry and regulatory
bodies to ensure that we have the right predictive models
that will benefit patients.
Modelling multichannel block. Alongside hERG-specific
drug interactions, it is increasingly clear that a
more complete pharmacological profile of individual
compounds needs to be considered in order to properly
assign risk (Mirams et al. 2011; Kramer et al. 2013),
and therefore needs to be described in silico as we work
towards holistic models of drug effects. Even a small
degree of mixed channel block can shorten or prolong
the QT interval by a few milliseconds, enough to be
measured in a clinical ECG study.However, it is not known
what (if any) risk is associated with these changes. It is
therefore important to understand whether small degrees
of block of multiple cardiac ion channels can combine
to give rise to increased proarrhythmia, or alternatively
perhaps confer some safety margin by compensating
for block that would ordinarily be proarrhythmic. Such
effects are certainly observed in the clinic, with drugs
such as verapamil and amiodarone for example, whose
multichannel pharmacology, especially block of cardiac
calcium channels, appear to significantly abrogate the
risk profile that would be associated with their block
of hERG. Mathematical models offer an intuitive and
biophysically based way to combine the effects of multiple
ion channel block in order to tackle this question.
In silico approaches based on concentration–effect data
derived from high-throughput drug screens on multiple
ion channels have been examined in this regard and
have shown good qualitative and quantitative agreement
with experimental results from rabbit ventricular wedge
preparations (Beattie et al. 2013) but less good pre-
diction of results from thorough QT studies (Mirams
et al. 2014), suggesting there is still work to be done
in this area. A limitation of these studies is that simple
concentration–effect data do not take into account
the full complexity of drug–channel interactions, such
as descriptions of binding and unbinding kinetics as
described above for hERG, meaning this is an obvious
area to address in seeking to improve in silico models of
multichannel block. It should be noted, however, that
development of Markov-type descriptions of channel
gating and pharmacology for multiple ion channels
represents a major undertaking, so once again warrants
careful consideration of the depth of characterisation that
is deemed necessary.
A second aspect to consider in relation to multichannel
block pertains to polypharmacy. Many, if not most,
adverse proarrhythmic effects are seen in patients who
are taking multiple drugs (‘torsade coadministration’
has > 16,700 hits on Google Scholar as of October
2015, see e.g. (Che´zalviel-Guilbert et al. 1995; Atar et al.
2003; Kounas et al. 2005; Kaz´mierczak et al. 2007).
With the correct application of in silico modelling of
multichannel pharmacology, predictions could be used
to avoid co-administration of particularly dangerous
compounds. This advance will require risk information to
be disseminated to the doctors in the clinic differently: risk
is no longer associated with the ‘black box’ for a particular
drug, but a new ‘black box’ would be generated for the
patient’s particular prescription. However, in this scenario
of combinations of compounds, each with multi-target
pharmacology, it is likely that historically trained statistical
modelswill not be capableof accuratepredictions– there is
quickly a combinatorial explosion with many risk factors;
so no training procedure will be able to assemble enough
cases to cover ‘all the options’ we may wish to consider.
For this reason, we consider that biophysically based
mechanistic models will continue to have a larger pre-
dictive advantage over purely statistical models in future.
Patient specific factors influencing the substrate
in aLQTS
The major focus of current regulatory guidelines is the
identification of compounds that carry risk of TdP.
However, even in the context of ‘dangerous drugs’, the
incidence of TdP is relatively low. For example, the
incidence of TdP in randomised trials of dofetilde is
reported to be 0.8–3.3% (Torp-Pedersen et al. 1999; Singh
et al. 2000). This raises the question of what makes these
subsets of patients vulnerable to drug-induced TdP? If we
were able to tackle this problem, itmay soonbeplausible to
move risk stratification from the pill to the patient, taking
into account the sub-groups that a patient falls into, in
termsof age, sex, genetic backgroundanddisease states.All
of these are well-recognised risk factors for proarrhythmia
(Zeltser et al. 2003; Frommeyer & Eckardt, 2015), and
are known to influence the electrophysiology of the cell
in ways that can be encapsulated in mathematical model
parameters (Yang & Clancy, 2012).
Genetic background. The concept of ‘repolarisation
reserve’ has provided the conceptual framework to under-
stand why a person’s genetic background may alter their
response to QT prolonging drugs (Roden, 2006). The
central tenet of this concept is that normal repolarisation
is a function of several redundant mechanisms, where
the overall repolarisation potential is determined by the
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 000.0 Computational cardiology and risk stratification 9
level of expression and function of multiple cardiac ion
channels, which in turn are coded for by an individual’s
genetic background. In this scenario, the effect of QT
prolonging drugs occurs in the context of different
electrical environments from person to person, meaning
the level of risk is specific to the individual.
Our ability to characterise this electrical background,
at least at the genetic level, has increased exponentially
with the advent of next generation sequencing. In this
regard, the early tranche of studies identified both cardiac
(Weeke et al. 2014) and non-cardiac (Jamshidi et al. 2012)
genes involved in risk determination in aLQTS. In this
time of precision medicine (Collins & Varmus, 2015),
in silico approaches hold the promise of (1) allowing us to
interpret this wealth of available data; (2) quantitatively
analyse the effect of variable genetic backgrounds;
(3) identify potentially protective and/or risky back-
grounds, and most importantly (4) make predictions
about how an individual or group of individuals may
respond to a QT prolonging drug. Early efforts to tackle
these questions have involved using multivariate analysis
to examinehowvariable genetic backgroundaltered action
potential duration (APD) prolongation in response to IKr
block (Sarkar & Sobie, 2011), and provide an excellent
platform for further in silico study of this area. At the
cellular level this approach could be extended to better
proarrhythmicmarkers such as triangulation or early after
depolarisations (EADs), while simulation of organ-level
effects will allow us to take into account tissue properties
relevant to proarrhythmia such as transmural dispersion
(Akar & Rosenbaum, 2003), alternative ECG markers
associated with risk (discussed below) and more complex
rate dependent effects. In this regard, the potential to
extend sensitivity analysis to the organ level now exists
(Sadrieh et al. 2014), and presents an opportunity to tackle
this problem in the coming years.
Tissue structure. A second factor to consider in
identifying patients at risk is the tissue structure of the
myocardium in each individual. A confounding effect in
the current approach is that early phase clinical trials
are carried out in cohorts of healthy individuals, and
consequently do not take into account potential patient
specific co-morbidities such as tissue structure alterations
that can influence the level of arrhythmia risk associated
with a drug. The patients at greatest risk of cardiac
adverse effects are likely to be those with pre-existing
heart disease and associated structural remodelling. For
example, the patchy fibrosis characteristic of ageing,
hypertensive heart disease and heart failure gives rise to
structural discontinuities across a range of scales that can
contribute to initiation of arrhythmia (Tanaka et al. 2007;
Tusscher et al. 2007). Furthermore, the more compact
fibrosis of healed myocardial infarcts can also provide a
focused substrate for circus re-entry (Jalife, 2000). It is
likely that such structural abnormalities couldhelp explain
the variability in risk profiles observed with drugs that
prolong theQT interval. This concept is supportedby early
clinical trials of antiarrhythmic drugs such as the Cardiac
Arrhythmia Suppression Trial (CAST) that was designed
to test the hypothesis that suppression of premature
ventricular complexes with class I antiarrhythmic agents
would reduce mortality after a myocardial infarction, but
instead found that the tested drugs actually decreased
survival (The Cardiac Arrhythmia Suppression Trial
(CAST) Investigators, 1989; Echt et al. 1991).
From the perspective of computational physiology,
multiple in silico approaches have already demonstrated
the role of structural discontinuity in arrhythmogenesis
(Caldwell et al. 2009; Engelman et al. 2010; Rutherford
et al. 2012). Specifically, it has been shown that patchy
fibrosis can give rise to re-entrant activation as well as
dynamic functional substrates that maintain re-entrant
circuits (Engelman et al. 2010). It is a short conceptual leap
to suppose that these structurally defined substrates and
triggers will amplify the specific proarrhythmic properties
of drugs in aLQTS. Of particular interest in this regard will
be an evaluation of rate dependent effects. For example,
drugs that interact with the hERG channel with different
kinetics and/or state dependence may well differentially
affect the rate dependent instability that arises from
structural defects such as fibrosis. A further factor to
consider regarding the role of structural alteration in
modifying risk is that the repolarisation heterogeneity,
which is thought to contribute to initiation of arrhythmias
in aLQTS, is amplified by structural remodelling (Akar &
Rosenbaum, 2003). In the structurally normal heart, this
heterogeneous repolarisation dispersion is modulated by
electrotonic coupling (Nattel et al. 2011) that one could
argue is reduced in structural heart disease, providing
further amplification of proarrhythmic effects. Such
problems, which are likely to include identifying precise
mechanistic features of drug binding that contribute to
structural-dependent risk modification, are very difficult
to tackle either in vivo or in vitro. However, in silico
approaches offer the flexibility to quantitatively address
these issues.
To achieve this, however, in addition to appropriate
molecular models of drug–channel interaction, will also
require high resolution structural imaging to provide
accurate and detailed meshes for in silico approaches.
Over the years imaging approaches have revealed detailed
laminar architecture of the heart including collagen
organisation and myofibre orientation that are critical in
defining electrical propagation. Similar approaches have
also been extended to imaging of infarct and peri-infarct
zones in animalmodels allowing in silico evaluationof how
electrical and structural disruptions interact to precipitate
potentially arrhythmic phenotypes (Rutherford et al.
2012; Deng et al. 2015). A critical area for development in
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this field, as we work towards clinical integration, will be
the continued growth of imaged-based analysis in human
subjects. Imaged-based models, that include details of
structural discontinuities exist for bothhumanatria (Zhao
et al. 2013;McDowell et al. 2015) and ventricles (Wallman
et al. 2014;Ukwatta et al. 2015),while recent developments
have focused on techniques and pipelines for extracting
useful structural meshes of human hearts and infarct
scars from standard medical imaging approaches (Crozier
et al. 2015; Ukwatta et al. 2015). These pipelines are
steps toward structure-based personalisation of in silico
approaches that will, over time, also establish populations
of cardiac structures. In the context of aLQTS, for example,
this will allow us to consider more broadly how electrical
disturbances that occur as adverse effects of drugs are
influenced by the range of structural discontinuities
present in human subjects, to provide a more nuanced
consideration of risk stratification in this area.
In silico driven risk stratification for aLQTS
Tackling the range of issues outlined above will provide
the necessary inputs to facilitate organ-level simulations
aimed at identifying ECG biomarkers that are more pre-
dictive of TdP than the current standard of using the QT
interval. Resolving this problem in silico embodies the
motivation of the Physiome project. Many of the issues
faced in risk prediction in aLQTS are related to the fact that
it is almost impossible to predict the path frommolecular
event – drug binding to an ion channel in this case –
to emergent properties of the cardiac electrical system
that might manifest on the ECG as a useful biomarker
for proarrhythmic risk. The ultimate goal for in silico risk
prediction is therefore to incorporate the factors discussed
above, including details of molecular interactions, cellular
biophysics, tissue structure and geometry of the heart,
into multiscale, organ level simulations that can predict
these emergent outputs, which can then be correlatedwith
the degree of risk associated with known compounds,
validated against clinical ECG data, and used for future
risk prediction.
Organ level simulations for identification of new ECG
biomarkers of risk. To date, in silico studies of the effects
of drug binding to hERG and other channels have largely
been focused at the cellular (Mirams et al. 2011; Beattie
et al. 2013; Romero et al. 2014) and pseudo-tissue level
(Roden & Viswanathan, 2005; Brennan et al. 2009),
and these studies have certainly highlight the potential
of the approach. The extension of this analysis to the
level of the organ is less developed, perhaps because of
the computational demands, or simply an acceptance
that simpler in silico approximations are, on balance,
a reasonable compromise given the shortcomings of
current molecular and cellular level models that we have
highlighted above.However, the feasibility of the approach
has been demonstrated in several recent studies. Zemzemi
et al. reported simulations from human torso and derived
a 12 lead ECG, including a basic representation of hERG
block (Zemzemi et al. 2013). More recently, quantitative
analysis of the molecular basis of the T wave based
on highly parallelised simulations of many thousands
of heartbeats, from hearts with different genetic and
molecular backgrounds, highlighted how the subtleties of
the T wave shape are related to underlying ion channel
conductances (Sadrieh et al. 2014). This parallelised
approach should prove especially useful when applied
to identification of new ECG biomarkers of risk. An
efficient approach might be to simulate many thousands
of ECGs from hearts with variable tissue structure and
geneticbackgrounds in thepresenceofdrugswithdifferent
kinetic properties and pharmacological profiles to create
a library of simulated ECGs that can be screened for ECG
biomarkers.
This of course begs the question of what specific
properties of the ECG waveform should be considered
in the search for these markers of risk? In this regard,
there is a growing appreciation that the morphology
of the T wave can help paint a much more complete
picture of cardiac electrophysiology (Vaglio et al. 2008;
Johannesen et al. 2014; Sadrieh et al. 2014; Vicente
et al. 2015). This idea is supported by clinical data that
illustrate how themorphology of the Twave is informative
about the range of ion channels blocked by a drug
(Vicente et al. 2015). More recently research from the
Mayo clinic has also demonstrated that specific aspects
of T wave morphology – specifically the slope of the
descending limb – are correlated with risk of TdP (Sugrue
et al. 2015). It therefore seems likely that features of
the morphology of the T wave on the ECG should be
a primary target in our search for new biomarkers. In
addition to this, dynamic features of the ECG (such as
temporal changes in QT interval and othermorphological
features of the signal) are a relatively neglected aspect
of the ECG that may contribute to better understanding
the various arrhythmogenic mechanisms associated with
single- and multi-channel drugs (Page et al. 2015). The
volume of data that can be generated representing a range
of pharmacological, genetic and environmental back-
grounds using parallelised in silico cardiac models pre-
sents an opportunity to study these dynamic features in
detail and develop them as a complementary facet to
T-wave morphology as ECG biomarkers for drug safety
and efficacy. Furthermore, the flexibility of simulation
relative tomore conventional in vitroor in vivo assays offers
the potential to interrogate a range of rate dependence
and complex stimulation protocols, and to correlate the
emergence specific ECG parameters with the onset of
arrhythmogenic properties (such as cellular EADS) and
even the initiation of TdP.
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The future: moving computational
cardiology into the clinic
There is still a huge amount of work to be done to
achieve the goal embodied in the human Physiome
project, i.e. being able to develop individualised in
silico models, in a realistic timeframe, that can help
determine the risk of cardiac arrhythmias in patients.
Success will require input from all sectors of the
biomedical research enterprise, spanning the academic,
industrial and clinical spheres and must be truly
multi-disciplinary. An integrative approach will involve
extensive detailed genotyping, comprehensive in vitro
and in vivo phenotyping of multiple systems including
electrical, calcium handling, imaging, contractile and
metabolic systems, and ultimately high performance
computer modelling to integrate the in vitro and in vivo
results to develop quantitative insights into the nature of
arrhythmogenic substrates and triggers. This approach,
combined with a ‘big data’ analysis of continuous
ECG traces will allow the identification of novel ECG
biomarkers that have much greater power to discriminate
between patients at high risk of proarrhythmic events
and those at low risk. Drawing from the experience in
the field of aLQTS discussed above, and the gaps in our
knowledge that it highlights, we submit that the following
specific goals should be pursued as a matter of priority to
accelerate the convergence of computational and clinical
cardiology:
1. A model of calcium cycling scalable to tissue and organ
level simulation.Modelling intracellular calcium, even
at the single cell level, is currently a bottleneck for
in silico studies of arrhythmia. Studies using many-
core accelerators such as Intel’s Xeon Phi or NVIDIA
GPU have mainly focused on increasing the spatial
resolution of simulating subcellular calcium down
to the nanometer. While these approaches tackle the
programming and performance challenges associated
with these architectures, our focus should be more
on numerical methods to work towards a multiscale
model of calcium cycling that can be scaled up to the
tissue level, albeit with necessary simplifications.
2. A consensus model of adrenergic effects on cardiac
electrophysiology.While adrenergic stimulation, either
as fight or flight surge, or increased basal tone
in the context of ischaemia has been implicated
in arrhythmogenesis, this factor is largely absent
frommodels of human ventricular electrophysiology.
Particular focus needs to be placed on developing
models of the effects of adrenergic stimulation on
the major components of repolarisation reserve (IKs,
ICaL), as well as intracellular calcium signalling in
human cells.
3. Development of IPSC derived cardiomyocytes for model
validation. Current uptake suggests IPSC derived
cardiomyocytes are set to play a major role as a source
of human tissue for validation of computer models of
cellular electrophysiology and pharmacology as well
as providing data to constraint models of particular
disease phenotypes. While this goal is outside the
immediate computational domain, development of
maturation strategies for these cells, such that data
can be obtained that is equivalent to adult human
tissue, is critical. Furthermore, since industry as well
is aggressively pursuing this goal, primarily as part
of the CiPA initiative, ongoing collaboration and
engagement with industry in this sector is the likely
the most productive and efficient approach.
4. Continuation of efforts to build central repositories and
tools for sharing and validation of models. The CellML
language and repository already provide a centralised
source formodel sharing, while the recently published
EP Web Lab allows standardised testing of these
models. This resource should be extended to
provide a centralised repository for published data,
protocols, structuralmeshes and associated validation
datasets such as in vitro electrophysiology and
clinical ECG data. The Physiome community should
explore working groups around facilitating such
resources.
5. Establishment of deep ECG phenotype resources.
Accurate phenotyping of ECG datasets is critical for
the iterative improvement of whole heart simulations
as well as identification and validation of novel ECG
biomarkers of risk identified in silico. Such analysis
is likely to involve detailed characterisation of ECG
wave morphology, as well as the dynamic changes
that are associated with emergence of ectopic triggers.
These types of analysis will necessitate use of data
from Holter and/or implantable loop recorder ECGs
to characterise how the heart responds to a wide range
of physiological stimuli as well as to capture relatively
infrequent, but information rich regions preceding
and following ectopic beats.
If such goals can be met, and can be demonstrated
to work in a relatively ‘simple’ case such as
aLQTS, this will provide an impetus to pursue
similar studies in other genetic arrhythmia syndromes
(Brugada syndrome, catecholaminergic polymorphic
ventricular tachycardia (CPVT), hypertrophic cardio-
myopathy (HCM), arrhythmogenic right ventricular
cardiomyopathy (ARVC)) and ultimately in the more
complex scenario of SCD complicating ischaemic heart
disease which involves electrical, calcium, metabolic and
structural remodelling.
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